MIVI Neuroscience Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference
Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3
Stay updated with breaking news from Stroke Conference. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3
This exploratory analysis of the SELECT2 trial assesses the relationship between imaging estimates of irreversibly injured brain (core) and at-risk regions (mis
Medtronic (NYSE: MDT) today announced new cost-effectiveness data from a study looking at its Reveal Linq insertable cardiac monitor (ICM).
Administering gingko biloba extract shortly after a stroke may help with cognitive recovery, according to a new study.
Innovative approaches in MRI technology demonstrate the potential of portable ultra-low-field MR brain imaging to aid physicians in the diagnosis of acute ischemic stroke ...